TABLE 1.
Demographic and laboratory parameters of aTTP patients
| 1 | 2 | 3 | 4 | Mean | |
|---|---|---|---|---|---|
| Gender | Female | Male | Female | Male | |
| Age (y) | 40 | 28 | 31 | 30 | 32 |
| aTTP episode | First | First | Relapse | Relapse | |
| Vaccination dose | Second | Second | First | Second | |
| Days following vaccination (N) | 8 | 28 | 13 | 8 | 14 |
| Baseline laboratory | |||||
| Hemoglobin gr/dl (N:11.7–15.7) | 9.9 | 9.1 | 7.7 | 10.8 | 9.4 |
| Platelets K/µl (N:140–450) | 12 | 38 | 15 | 11 | 19 |
| Creatinine mg/dl (N:0.5–1.0) | 0.92 | 1.5 | 1.2 | 1.44 | 1.26 |
| LDH U/l (N: 240–480) | 7129 | 3063 | 4000 | 1544 | 3169 |
| Schistocytes % | 6 | 6 | 10 | 6 | 7 |
| Troponin ng/ml (N <0.03) | 0.01 | 0.12 | NA | NA | |
| PEX sessions (N) | 6 | 5 | 4 | 5 | 5 |
| Time to responsea, days | 3 | 4 | 3 | 5 | 4 |
| ADAMTS‐13 activity IU/ml (N: 0.4–1.3) (%) | |||||
| Baseline | 0 | 0 | 0 | 0 | 0 |
| At 5 weeks | 0.52 (40) | 0.77 (60) | 0 | 0.6 (46) | 0.47 (37) |
| ADAMTS‐13 antibodies U/ml (N: 0–15) | |||||
| Baseline | 51 | 113 | 64 | 21 | 62 |
| At 5 weeks | 1.9 | 8.9 | 10 | 10 | 7.7 |
Abbreviations: aTTP, acquired thrombotic thrombocytopenic purpura; ADAMTS‐13, A Disintegrin and Metalloproteinase with a ThromboSpondin type 1 motif, member 13; LDH, lactic acid dehydrogenase; NA, not applicable; PEX, plasma exchange.
a
Defined as platelets>150 k/µl and LDH <1.5xULN.